MYSTIC, Conn. and DUBLIN, Jan. 11, 2011 /PRNewswire/ — Amarin
Corporation plc (Nasdaq:
AMRN) (the “Company”), a clinical-stage biopharmaceutical
company with a focus on cardiovascular disease, today announced
that it has completed its previously announced underwritten public
offering of American Depositary Shares (“ADSs”) at a price to the
public of $7.60 per ADS.

Due to the exercise in full of the underwriters’ over-allotment
option, the company sold a total of 13,800,000 ADSs in the offering
for an aggregate public offering amount of approximately $104.9
million, and received approximately $100.2 million of net proceeds
from the offering, after deducting the underwriting discount and
estimated expenses of the offering payable by the company.

Amarin anticipates using the net proceeds from the offering to
prepare for the commercialization of AMR101, file a New Drug
Application and for working capital and general corporate
purposes.

Jefferies & Company, Inc. and Leerink Swann LLC acted as
joint book-running managers for the offering and Canaccord Genuity
Inc. acted as co-lead manager for the offering.

The securities described above were offered by Amarin pursuant
to a shelf registration statement previously filed with and
declared effective by the Securities and Exchange Commission (the
“SEC”) on November 23, 2010. A final prospectus supplement related
to the offering has been filed with the SEC and is available on the
SEC’s website at http://www.sec.gov. Copies of the
final prospectus supplement relating to these securities may be
obtained from Equity Syndicate Prospectus Department, Jefferies
& Company, Inc., 520 Madison Avenue, 12th Floor, New York, NY,
10022, at 877-547-6340, and at
Prospectus_Department@Jefferies.com. This news release shall
not constit

‘/>”/>

SOURCE